Dr Mark Basik is a surgical scientist Head of the Cancer Genomics and Translational Research Laboratory at the Lady Davis Institute and Associate professor in the Departments of Surgery and Oncology at McGill University. He is the Medical Director of the Inter-disciplinary Breast Cancer Team at the Segal cancer Center at the Jewish General Hospital and his laboratory is involved in the development of novel cutting-edge technology for biomarker discovery and validation in breast cancer. Dr. Basik is part of the FRQS Réseau de Cancer axe cancer du sein/ovaire, and as such, actively participates in a province-wide breast tumor and plasma banking in breast cancer. His primary interests are the investigation of gene expression and DNA changes in breast and colon cancer, discovery of tumor suppressor genes, mechanisms of resistance to anti-cancer drug therapies, discovery and validation of tissue and plasma biomarkers of breast cancer outcome and response to treatment, with a special focus on triple negative breast cancer. Dr.Basik and his team are working in translational-cancer research which aims at bridging basic and clinical research for the benefit of cancer patients.